BBNX Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.0% since its last earnings release on July 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease.
Sector
Healthcare
Industry
Medical Appliances/Equipment